ClinicalTrials.gg
CompletedNCT07076446Updated Jul 16, 2026

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

A Phase 4 interventional study of IgPro in Primary Immunodeficiency, sponsored by CSL Behring. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by CSL Behring (part of CSL Limited) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Primary Immunodeficiency Diseases by CSL Limited — none open to participants now, none under way, none of them phase 3. Primary Immunodeficiency Diseases · CSL Limited.

Enrollment
13th of 13
8 · median 25
Started
2025
the only one that year
Phase 4
4 of 14
none open now
Registered
14th of 14
by date

Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 4, and was the 14th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

None of the 14 studies in Primary Immunodeficiency Diseases by CSL Limited is open now. The open studies under Primary Immunodeficiency Diseases, anywhere →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Primary Immunodeficiency Diseases by CSL Limited as a file.
02

Study summary

This is an open-label, multicenter, phase 4 study in IG treatment-naïve participants with PID, conducted in the United States (US), to assess the PK, safety, and tolerability of IgPro20. The primary objective of this study is to characterize the PK of IgPro20 and to assess the safety and tolerability of IgPro20 in IG treatment-naïve participants with PID who are aged greater than or equal to (>=) 18 years.

03

Conditions studied

  • Primary Immunodeficiency

Keywords

  • Immunoglobulin replacement therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be aged >=18 years.
  • Participants must have a confirmed and documented diagnosis of PID, must be IG treatment-naïve and have an IgG level less than or equal to (\<=) 400 milligrams per deciliter(mg/dL) at Screening.

Exclusion criteria

Exclusion Criteria:

  • Participants with hyperprolinemia.
  • Participants who are receiving the following medications:
  • Systemic (prednisone or equivalent; average daily dose of greater than [>] 15 mg) from 4 weeks before Screening.
  • Any dose of systemic within 9 months or 5 times the half-life (t½) plus 6 months before Screening, whichever is longer.
  • Any dose of biologic therapies with influence on the immune system (eg, tumor necrosis factor inhibitors, interleukin inhibitors, B-cell inhibitors), including agents, within 12 months or 5 times the t½ plus 6 months before Screening, whichever is longer.
  • Participants who are currently receiving anti-coagulation therapy.
  • Participants with hypoalbuminemia, protein-losing enteropathies, and kidney diseases with proteinuria.
  • Participants with a documented history or a current diagnosis of a thromboembolic event(s) (eg, deep vein thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular accident, ) or coagulopathy within 12 months before Screening.
  • Participants with severe dehydration and known blood disorders affecting viscosity.
  • Participants with and alanine aminotransferase concentration > 3 times the (ULN; central laboratory) at Screening.
  • Participants with creatinine concentration > 1.5 times the ULN (central laboratory) at Screening.
  • Participants with new onset or worsening or severe cardiac, pulmonary, kidney disease, and liver disease.
  • Participants with of lymphoid cells such as chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and immunodeficiency with thymoma.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    IgPro20

    All participants will receive a loading dose of IgPro20 daily from Day 1 to 5 in Week 1, followed by weekly administration of the maintenance dose of IgPro20 from Day 8 (Week 2) to Day 78 (Week 12).

    Biological: IgPro

Interventions

  • BiologicalIgPro

    IgPro20 is a solution for infusion for subcutaneous administration.

    Also known as: Immune globulin subcutaneous (Human) 20% liquid

06

What researchers measure

Primary outcomes

  1. Trough concentration (Ctrough) Levels of IgPro20

    Time frame: Up to Week 13

  2. Number of Participants Experiencing Any Treatment-Emergent Adverse Event (TEAEs) or Serious TEAEs

    Time frame: Up to Day 85

  3. Number of TEAEs and Serious TEAEs Events

    Time frame: Up to Day 85

  4. TEAEs and Serious TEAEs Event Rates Per Days with Infusion

    Time frame: Up to Day 85

07

Study locations

8 sites
  • Research Solutions of AZ
    Litchfield Park, Arizona 85340, United States
  • Medical Research of Arizona
    Scottsdale, Arizona 85251, United States
  • Immunoe Health Centers
    Centennial, Colorado 80112, United States
  • Johns Hopkins Bayview Medical Center
    Baltimore, Maryland 21224, United States
  • Midwest Immunology
    Plymouth, Minnesota 55446, United States
  • Washington University
    St Louis, Missouri 63141, United States
  • Allergy, Asthma and Clinical Research Center
    Oklahoma City, Oklahoma 73120, United States
  • Allergy & Clinical Immunology
    Pittsburgh, Pennsylvania 15241, United States
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.

Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Jun 2026, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Jul 22, 2025
StartActual
Jul 15, 2025
Primary completionActual
Jun 30, 2026
CompletionActual
Jun 30, 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07076446
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jul 22, 2025
Start date
Jul 15, 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Jul 16, 2026

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins

Start the discussion